Groupama Asset Managment Acquires 10,273 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 90,612 shares of the biopharmaceutical company's stock after buying an additional 10,273 shares during the quarter. Groupama Asset Managment owned 0.08% of Regeneron Pharmaceuticals worth $57,752,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. Vanguard Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after acquiring an additional 174,056 shares during the last quarter. Northern Trust Corp grew its stake in shares of Regeneron Pharmaceuticals by 14.8% during the 4th quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company's stock worth $751,386,000 after acquiring an additional 136,184 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Regeneron Pharmaceuticals by 30.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after purchasing an additional 226,952 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on REGN shares. Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $8.68 during midday trading on Friday, hitting $589.48. The company's stock had a trading volume of 1,438,624 shares, compared to its average volume of 1,111,801. The stock has a market capitalization of $62.48 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 1.97 and a beta of 0.33. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company's fifty day simple moving average is $549.27 and its two-hundred day simple moving average is $592.95. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the prior year, the business earned $11.56 earnings per share. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.